(23 April 2020) Baricitinib- none of the baricitinib-treated patients required admission to ICU

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177073/

Baricitinib at 4 mg/day/orally was given to 12 patients with moderate COVID-19.  In baricitinib-treated patients no adverse events were recorded and clinical and respiratory parameters significantly improved in 2 weeks. None of the baricitinib-treated patients required admission to ICU.